This article is a correction to:
Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390
Xiaozhi Lv
Junyan Wu
Herui Yao
Suiwen YeA Corrigendum on
Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390
by Wu J, Yao H, Lv X, Ye S and Zhang N (2022). Front. Drug. Discov. 2:963045. doi: 10.3389/fddsv.2022.963045
In the published article, there was an error in the Author list, and author Xiaozhi Lv was erroneously listed as the third author, not the first. The corrected Author list appears below.
“Xiaozhi Lv, Junyan Wu*, Herui Yao*, Suiwen Ye, Nan Zhang”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
In the published article, there was an error in the Funding statement. It was erroneously left out. The correct Funding statement appears below.
Funding
The authors declare that financial support was received for the research, authorship, and/or publication of this article. Funding went to principal investigator JW for the name of the clinical trial sponsor—itraconazole against SHR6390 in healthy subjects trial. This study was funded by Jiangsu Hengrui Pharmaceutical Co., Ltd. The involvement of funder in the study is as follows: the funders only participated in the design of national clinical trials, and the subsequent data collection, analysis and interpretation were all completed by the researchers of our center. The funders did not participate in the writing of this paper or the decision of whether to publish it.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: SHR6390, itraconazole, pharmacokinetic, safety, drug-drug interaction, healthy subjects
Citation: Lv X, Wu J, Yao H, Ye S and Zhang N (2024) Corrigendum: Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390. Front. Drug Discov. 4:1397200. doi: 10.3389/fddsv.2024.1397200
Received: 20 March 2024; Accepted: 08 April 2024;
Published: 17 April 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Lv, Wu, Yao, Ye and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Junyan Wu, wujunyan@mail.sysu.edu.cn; Herui Yao, yaoherui@mail.sysu.edu.cn